Moderna's personalized mRNA melanoma vaccine, Intrismeran, met its primary goal in a Phase 2b trial.
The vaccine, in combination with Merck's Keytruda, showed improved recurrence-free survival in melanoma patients.
Positive trial results position Moderna for potential Phase 3 studies and bolster its oncology pipeline.
👉 Read the full institutional analysis, options flow, and live charts on BuzzTickr.com »
Top comments (0)